Canaccord Genuity initiated coverage on Thorne HealthTech with a new price target

$THRN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $THRN alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $THRN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$THRN

DatePrice TargetRatingAnalyst
11/17/2022$5.50Buy
Canaccord Genuity
10/18/2021$11.00Buy
B of A Securities
10/18/2021Buy
BofA Securities
10/18/2021$13.00Outperform
Evercore ISI Group
10/18/2021$11.00Outperform
Cowen & Co.
10/18/2021$11.00Outperform
RBC Capital
More analyst ratings

$THRN
Press Releases

Fastest customizable press release news feed in the world

See more
  • L Catterton and Thorne HealthTech, Inc. Announce Expiration of Tender Offer

    NEW YORK, Oct. 13, 2023 /PRNewswire/ -- L Catterton and Thorne HealthTech, Inc. ("Thorne") (NASDAQ:THRN) today announced that the tender offer to purchase all of the issued and outstanding shares of Thorne's common stock ("Shares") for $10.20 per Share, net to the seller in cash, without interest and less any required withholding taxes (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on October 12, 2023 and was not extended (such date and time, the "Expiration Time"). Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised L Catterton that, as of the Expiration Time, 52,596,517 Shares were validly tendered and not validly

    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lifshitz Law PLLC Announces Investigations of ABCM, THRN, BHRB, and AGE

    NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Abcam Plc (NASDAQ:ABCM) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ABCM to Danaher Corporation for $24.00 per share in cash for each share of ABCM common stock owned. If you are an ABCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com. Thorne HealthTech, Inc. (NASDAQ:THRN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TRHN to L Catter

    $ABCM
    $BHRB
    $THRN
    $AGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Banks
    Finance
  • Thorne HealthTech, Inc. Enters into Definitive Agreement to be Acquired by L Catterton for $10.20 Per Share in Cash

    L Catterton to Commence a Tender Offer for all of Thorne's Outstanding Shares of Common Stock Thorne Stockholders to Receive $10.20 per Share in Cash, Representing a 94% Premium to the Unaffected Price Independent Special Committee and Thorne Board of Directors Unanimously Approve Transaction and Recommend that All Stockholders Tender Their Shares in the Tender Offer  NEW YORK, Aug. 28, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused inv

    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$THRN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$THRN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$THRN
SEC Filings

See more

$THRN
Leadership Updates

Live Leadership Updates

See more
  • Thorne HealthTech Appoints Saloni Varma as New Chief Financial Officer

    NEW YORK, March 13, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ:THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced that it has appointed Saloni Varma as Chief Financial Officer (CFO). As CFO, Varma will lead all aspects of the company's Accounting and Finance functions including budgeting planning and analysis, accounting, SEC reporting, tax, treasury, and investor relations. Varma brings more than 20 years of experience across a range of consumer goods companies, mos

    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$THRN
Financials

Live finance-specific insights

See more
  • Thorne HealthTech Reports Second Quarter 2023 Results

    Record Net Sales With Growth of 33.1%; Raises Full-Year Guidance Midpoints for Net Sales and Gross Margin NEW YORK, Aug. 8, 2023  /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the second quarter ended June 30, 2023. Second Quarter Highlights: Net sales grew 33.1% year-over-year to $72.7 million, with direct-to-consumer ("DTC") sales growth of 39.3%Gross profit grew 35.7% year-over-year to $40.6 million; gross profit as a % of net sales increased year-over-year to 55.9%.Net incom

    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Thorne HealthTech Schedules Second Quarter 2023 Earnings Release and Conference Call for August 8

    Company Withdraws Participation in the Canaccord Genuity 43rd Annual Growth Conference on Aug. 10 NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, will release its second quarter 2023 financial results after market close on Tuesday, Aug. 8, 2023. The company will host a conference call to discuss its results on Tuesday, Aug. 8, 2023, at 5:00 p.m. (U.S. Eastern Time). A live webcast and replay of the call will be available on the investors section of the

    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Thorne HealthTech Reports First Quarter 2023 Results

    Net Sales Growth of 20.7%; Reaffirms Full-Year 2023 Guidance NEW YORK, May 11, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Highlights: Net sales grew 20.7% year-over-year to $65.2 million, with direct-to-consumer ("DTC") sales growth of 41.0%Gross profit grew 16.3% year-over-year to $34.3 million; gross p

    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$THRN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more